RecruitingEUCTR 2021-000350-26
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Kazanlik and 40 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Oryzon Genomics, S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Bulgaria, Poland, Romania, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2021-000350-26
- Official title
Show the full official title
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
Recruitment & locations
RecruitingKazanlik, Bulgaria · Lovech, Bulgaria · Novi Iskir, Bulgaria
33 more locations
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Razgrad, Bulgaria
- Ruse, Bulgaria
- Sliven, Bulgaria
- Sofia, Bulgaria
- Sofiya, Bulgaria
- Varna, Bulgaria
- Gdansk, Poland
- Lublin, Poland
- Olkusz, Poland
- Poznan, Poland
- Zabrze, Poland
- Bucharest, Romania
- Cluj-Napoca, Romania
- Jassi, Romania
- Selimbar, Romania
- Sibiu, Romania
- Kosice - Zapad, Slovakia
- Stare Mesto, Slovakia
- Vranov Nad Toplou, Slovakia
- Alcorcon, Spain
- Barcelona, Spain
- Burgos, Spain
- Elche, Spain
- Madrid, Spain
- Malaga, Spain
- Oviedo, Spain
- Pamplona, Spain
- Sevilla, Spain
- Torrejon De Ardoz, Spain
- Vigo, Spain
- Zamora, Spain
Registry details
Original registry record (opens in a new tab)Current country statuses
Historical country statuses
- Spain — Ongoing
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Oryzon Genomics, S.A.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
